Business Wire

NY-ESTÉE-LAUDER

Share
The Estée Lauder Companies Announces New Equity and Engagement Center of Excellence

The Estée Lauder Companies (NYSE:EL) announced today that it has established a new Equity and Engagement Center of Excellence (COE). The creation of this new capability underscores The Estée Lauder Companies’ (ELC) core values and commitments to build greater equity and representation within every aspect of its business, from its employees to its consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005218/en/

The Equity and Engagement COE will be led by Nicole Monson , who has been appointed Senior Vice President, Equity and Engagement. Nicole will report directly to Michael O’Hare, Executive Vice President, Global Human Resources.

The events of 2020 and the movement around racial equality have placed a necessary spotlight on every company’s responsibility to take action to advance equal representation, advocacy and inclusion across their organizations. From examining and evolving how the company engages with employees around the world, to enabling greater collaboration across its brands, regions and functions, ELC remains dedicated to purposeful, strategic and accelerated action to drive lasting change.

Building upon ELC’s existing Commitment to Act on Racial Equity , actions on pay equity and other activities to date, the creation of the Equity and Engagement COE signals ELC’s investment in a focused and holistic approach to drive sustainable progress and advance the company’s diverse talent through deep engagement, career advancement, development programs, hiring practices and beyond.

“Our collective vision is to be the most inclusive, equitable and diverse global prestige beauty company for our employees and consumers alike. This important new capability will enhance employee engagement and build greater equity across the business today, while also providing a strategic platform to expand and scale this work into the future,” said Fabrizio Freda, President and Chief Executive Officer . “We know that authentic change takes time, dedication and a clear strategy, and we will continue to devote focused and meaningful resources toward accelerating this goal.”

“Since our company’s founding, our talented employees have been at the center of our business and the most important driver of our success. While we are proud of the progress we have made as a company thus far, we are committed to driving equity and engagement for the long-term,” said William P. Lauder, Executive Chairman . “Nicole’s deep experience and extensive knowledge of Human Resources and the global legal environment, combined with her demonstrated ability to positively influence ELC’s culture, have been invaluable to the company. I look forward to her continued leadership at the helm of this new Center of Excellence.”

As Senior Vice President, Equity and Engagement, Nicole will be an important member of ELC’s Senior Leadership Team and she will work across all areas of the business to develop the company’s long-term Equity and employee Engagement strategy and enterprise-wide capabilities. She will lead the development and implementation of proactive Equity and Engagement initiatives to create a workforce that is more representative and responsive to people of all backgrounds, where all have an opportunity to succeed.

The Equity and Engagement COE was designed to be a strategic and complementary enterprise-wide partner to ELC’s other leaders and business units focused on ESG-related matters, including Human Resources, the Inclusion, Diversity & Equity (IDE) COE, Global Communications, Global Citizenship and Sustainability (GCCS), Global Public Affairs, and beyond. In this spirit, Nicole will collaborate closely with Human Resources leaders and the IDE COE to develop programs designed to ensure fair, inclusive, and equitable treatment of employees around the world with emphasis on addressing conflict and implementing support systems for employees of color, ensuring equitable compensation, application of policies and access to career paths and ensuring the execution of ELC’s equity and engagement vision and strategy. Additionally, Nicole will lead the company’s Racial Equity Initiative, which includes finalizing and implementing a strategy to ensure ELC achieves its Racial Equity Commitments.

Nicole has an extensive proven track record of providing business partners with strategic legal counsel on a wide range of employment and compliance topics, a background that will serve her well in her new role. In her most recent position as Senior Vice President, Deputy General Counsel, Global Employment, Ethics and Legal Privacy, Nicole oversaw the Employment Law, Ethics and Legal Privacy teams and worked to advance the Legal strategy for employment, ethics and privacy globally to protect the company’s interests and mitigate risks associated with new laws and regulations, growth of digital platforms, new global acquisitions and an increased regulatory environment. Since joining the company in 2014 as Vice President, Employment Counsel, her role has continuously expanded and evolved with new responsibilities.

Nicole’s influence on ELC’s organizational culture has extended far beyond her official role and responsibilities. As a member of ELC’s Diversity Council, as well as ELC’s ‘Network of Black Leaders & Executives’ and ‘Women’s Leadership Network’ Employee Resource Groups, Nicole has long been passionate about promoting a culture of respect, inclusivity and belonging. Recently, she became Executive Sponsor of She’s Howard: Own Your Power , ELC’s partnership with Howard University to support the success of the University’s alumnae through experiential learning, career coaching, professional training and self-empowering mentorship opportunities.

In addition to her many contributions to ELC, Nicole is a highly regarded expert and thought leader. She has been a guest speaker for numerous local and national organizations. Notably, Nicole was also selected for inclusion into the National Black Lawyers Top 100 , an elite network of successful and influential lawyers with reputations for providing excellent legal representation in their respective practice areas.

Nicole has more than 20 years of relevant experience across labor and employment law and compliance. She earned her J.D. from Howard University School of Law and her B.A. from Spelman College.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye